Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Distinct prognostic value of [Communications medicine · 2026Article
- The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[Asian journal of urology · 2024Article
- Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?Cancers · 2023Review
- Clinical advancement of precision theranostics in prostate cancer.Frontiers in oncology · 2023Review
- The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.Biomedicines · 2022Review
- Review
- A Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Beyond the Prognostic Value of 2-[Diagnostics (Basel, Switzerland) · 2022Review
- The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.Prostate cancer and prostatic diseases · 2021Article
- Article
- Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Drug Repurposing of Pantoprazole and Vitamin C Targeting Tumor Microenvironment Conditions Improves Anticancer Effect in Metastatic Castration-Resistant Prostate Cancer.Frontiers in oncology · 2021Article
- The Evolving Role ofFrontiers in oncology · 2021Article
- GLUT1 expression in high-risk prostate cancer: correlation withProstate cancer and prostatic diseases · 2020Article
- A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Review
- Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.Theranostics · 2020Article
- Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?Therapeutic advances in medical oncology · 2019Review
- Advanced modalities of molecular imaging in precision medicine for musculoskeletal malignancies.World journal of nuclear medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aim of this prospective investigation was to assess the association of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.